Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms
Authors:
- 1 February 2019
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 67, 160-175
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (2017KFYXJJ151, 81473254, U170311, 81773637, 81773594)
- Fundamental Research Funds for the Central Universities (2017KFYXJJ151, 81473254, U170311, 81773637, 81773594)
- National Natural Science Foundation of China (2017KFYXJJ151, 81473254, U170311, 81773637, 81773594)
This publication has 112 references indexed in Scilit:
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Nature Immunology, 2012
- Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infectionNature Immunology, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerProceedings of the National Academy of Sciences, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 2010
- Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient OutcomeCancer Research, 2009
- B7 Blockade Alters the Balance between Regulatory T Cells and Tumor-reactive T Cells for Immunotherapy of CancerClinical Cancer Research, 2009
- How regulatory T cells workNature Reviews Immunology, 2008
- Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and PeripheryImmunity, 2008